Peregrine Pharma (NASDAQ: PPHM) announced the first of four presentations of clinical and preclinical data related to the company’s immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab. Data from today’s presentation show that the combination of a phosphatidylserine (PS)-targeting antibody equivalent to bavituximab and an antibody targeting the immune checkpoint CTLA-4 yielded statistically significant anti-tumor effects as compared to the anti-CTLA-4 antibody alone.
MRV Research
Myriad myPath(TM) Melanoma Improves Diagnosis and Treatment Plans
Myriad Genetics, Inc. today presented results from a prospective clinical utility study of its Myriad myPath Melanoma test at the 2014 American Society of Dermatopathology (ASDP) annual meeting in Chicago, Ill. Myriad myPath Melanoma is a genetic test that differentiates malignant melanoma from benign skin lesions across all major melanoma subtypes.
Uveal Melanoma Successfully Treated with Lower Doses of Radiation
Rare as it is, uveal melanoma–or cancer in the eye involving the iris, cilliary body, or choroid–is the most common primary cancer of the eye, according to the National Cancer Institute. Treatment of uveal melanoma is achieved with radiation therapy, although a variety of regimens and techniques have been applied successfully.
Combination treatment for metastatic melanoma results in longer overall survival
Among patients with metastatic melanoma, treatment with a combination of the drugs sargramostim plus ipilimumab, compared with ipilimumab alone, resulted in longer overall survival and lower toxicity, but no difference in progression-free survival, according to a study in the November 5 issue of JAMA.